Pacritinib in Patients with Myelofibrosis-Reply

Affiliations

Comment

John O Mascarenhas. JAMA Oncol. 2018.

. 2018 Dec 1;4(12):1787.

doi: 10.1001/jamaoncol.2018.4842.

¹ Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.

No abstract available

Comment on

Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.
Mascarenhas J, Hoffman R, Talpaz M, Gerds AT, Stein B, Gupta V, Szoke A, Drummond M, Pristupa A, Granston T, Daly R, Al-Fayoumi S, Callahan JA, Singer JW, Gotlib J, Jamieson C, Harrison C, Mesa R, Verstovsek S. Mascarenhas J, et al. JAMA Oncol. 2018 May 1;4(5):652-659. doi: 10.1001/jamaoncol.2017.5818. JAMA Oncol. 2018. PMID: 29522138 Free PMC article. Clinical Trial.
Pacritinib in Patients With Myelofibrosis.
Suzuki S, Tsuda K, Tanimoto T. Suzuki S, et al. JAMA Oncol. 2018 Dec 1;4(12):1786-1787. doi: 10.1001/jamaoncol.2018.4830. JAMA Oncol. 2018. PMID: 30422169 No abstract available.